LBRX
LB PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$38.81
+5.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +60.5%
- EBIT
- +53.1%
- Net income
- +60.1%
- EPS
- +94.4%
- Free cash flow
- +34.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026